Survey and Monitoring of the prevalence of MRSA, MSSA and CNS of patients with elective orthopedic and cardiovascular interventions
Recruiting
- Conditions
- U80.0
- Registration Number
- DRKS00004261
- Lead Sponsor
- Forschungslabor für Biomechanik und Implantattechnologie OrthopädischeKlinik und Poliklinik, Universitätsmedizin Rostock
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
• aged 18 to 80 years
• elective surgical procedures in the hip and knee replacements, artificial heart valves and cardiac pacing and use of cardiovascular stent implantation
• The ability to understand the scope and significance of the trial and take part in the willingness and ability of the necessary follow-up
• existence of a written consent form
Exclusion Criteria
• presence of a tumor disease
• Known allergy to used materials
• nursing and pregnant women and those women planning to become pregnant during the trail period
• non-availability for the duration of the trial
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measure is the analysis of the microbial spectrum and the prevalence of MRSA, MSSA and CNS in microbiological swabs of the skin, nose and throat in patients with elective surgery in the hip and knee replacements, artificial heart valves and cardiac pacing applications, as well as cardiovascular stent implantation.<br>The patients will be screen with swabs from the groin, nose and throat swabs and operated area before the interventions and immediately before discharge. The will be tested for MRSA and KNS (microbiological culture methods). After a 12-month follow-up the patients will be ask by telephone to a questionnaire on infection-procedure in the operated area.
- Secondary Outcome Measures
Name Time Method The secondary objective criterion is the detection frequency of intervention-associated infections within the follow-up of 12 months.